A small Melbourne company founded by two medical researchers has landed one of Australia's biggest potential licensing deals.
AusBiotech says the Government's R&D tax bill still penalises the clinical trial and manufacturing companies Australia most ...
Melbourne biotech Magellan Stem Cells is 17 years old and about to begin a pivotal Phase 3 trial of its stem cell treatment ...
Neurizon Therapeutics has finished enrolling its pivotal ALS trial ahead of schedule. The US Food and Drug Administration has ...
The Melbourne company dosed the first patient in its Beyond Harmony study of NTI164 on 21 September. All six sites across ...
Nyrada has raised $0.73 million before costs through a Securities Purchase Plan (SPP), topping up funds from its September ...
BCAL Diagnostics has secured a seat on Genetic Signatures' board, though it is only part of what it asked for. At an ...
A Greek study of an Australian-developed radioactive implant found that tumours stopped growing in every patient assessed at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results